MetaCap

Heartflow Inc. (HTFL)

NASDAQ: HTFLHealth CareMedical/Dental InstrumentsUSD

46.69+2.06 (+4.62%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

HTFL stock chart

Technical analysis

Key statistics

All statistics
52-week range
20.13 – 60.66
Day range
43.78 – 47.16
Volume / Avg
1.89M / 1.84M
Beta
—

52-week range

$20.13$60.66

HTFL stock today

Shares of Heartflow (HTFL) finished higher on Nov 20 at $46.69, a gain of 4.62% or $2.06 per share, versus the S&P 500's 3.70% decline. At this level, HTFL sits in the middle of its 52-week range of $20.13 to $60.66: 23.0% below the high, set on Nov 11, 2026 and 131.9% above the low. HTFL is up 60.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 51.3%.

At 69.7x trailing earnings, Heartflow trades above the peer-group median of 31.6x.

Summary generated from market data by MetaCap's automated system. Methodology

About Heartflow

Company profile

HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies.

Industry
Medical/Dental Instruments
CEO
Mr. John C.M. Farquhar
Headquarters
San Francisco, CA
Employees
843
IPO year
2025

Financial highlights

Full financials

In fiscal 2025, Heartflow generated $176.0 million in revenue, up 39.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Heartflow reported a net loss of $116.8 million, compared with a loss of $96.4 million a year earlier. Gross margin was 76.8% (up from 75.1%) and operating margin -36.4%.

Heartflow annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$176.03M$125.81M$87.17M
Growth+39.92%+44.32%—
Net income$-116.79M$-96.43M$-95.66M
EPS (diluted)$-3.17$-17.98$-25.32

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$65.00+39.22%

  • Strong buy 2
  • Buy 6
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $59.00High $70.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.35 vs $-0.18
Surprise
-94.44%

HTFL news

All HTFL news

Heartflow peers

Health Care sector
HTFL peer companies
CompanyPrice% ChgMarket capCompare
STVNStevanato Group S.p.A.15.65-1.76%$4.27Bvs HTFL
ICUIICU Medical Inc.172.52-1.84%$4.31Bvs HTFL
MMEDMiniMed Group Inc.16.01-1.54%$4.50Bvs HTFL
NVSTEnvista Holdings Corporation22.91-1.55%$3.67Bvs HTFL
PLSEPulse Biosciences Inc45.55+2.57%$3.35Bvs HTFL
IRTCiRhythm Holdings Inc.94.72+0.51%$3.18Bvs HTFL
MMSIMerit Medical Systems Inc.84.34-0.08%$5.05Bvs HTFL
ATRCAtriCure Inc.55.39+2.37%$2.82Bvs HTFL

Indexes, lists and sector

Heartflow stock FAQ

What is Heartflow's stock price today?

HTFL last traded at $46.69 as of Nov 20, 4:00 PM EST, up 4.62% on the day. Prices are delayed at least 15 minutes.

What is HTFL's P/E ratio?

HTFL trades at a trailing P/E ratio of 69.69, compared with a median of 31.6 for its closest peers.

Who is Heartflow's CEO?

Mr. John C.M. Farquhar is the chief executive officer of Heartflow Inc., which has about 843 employees.

What is the HTFL 52-week high?

The 52-week high for HTFL is $60.66 and the 52-week low is $20.13. The stock is currently 23.0% below its high.

Compare HTFL